Patents by Inventor Andrew Polson

Andrew Polson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-B7-H4 antibodies and immunoconjugates
    Patent number: 12281165
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: February 22, 2022
    Date of Patent: April 22, 2025
    Assignee: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
    Publication number: 20250073212
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: May 10, 2024
    Publication date: March 6, 2025
    Applicant: Genentech, Inc.
    Inventors: Andrew POLSON, Shang-Fan YU, Yu-Waye CHU, Michael WENGER, Jamie Harue HIRATA, Dan LU
  • Anti-B7-H4 antibodies and immunoconjugates
    Patent number: 12134649
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: November 5, 2024
    Assignee: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
    Publication number: 20240309088
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: December 21, 2023
    Publication date: September 19, 2024
    Applicant: Genentech, Inc.
    Inventors: Yvonne CHEN, Mark DENNIS, David DORNAN, Kristi ELKINS, Jagath Reddy JUNUTULA, Andrew POLSON, Bing ZHENG
  • Methods of using anti-CD79b immunoconjugates
    Patent number: 12016842
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: June 25, 2024
    Assignee: Genentech, Inc.
    Inventors: Andrew Polson, Shang-Fan Yu, Yu-Waye Chu, Michael Wenger, Jamie Harue Hirata, Dan Lu
  • Humanized anti-CD79B antibodies and immunoconjugates and methods of use
    Patent number: 11866496
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: January 9, 2024
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
    Publication number: 20220298161
    Abstract: Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer.
    Type: Application
    Filed: January 27, 2022
    Publication date: September 22, 2022
    Inventors: Philip Wilson HOWARD, Luke MASTERSON, Arnaud TIBERGHIEN, John A. FLYGARE, Janet L. GUNZNER, Paul POLAKIS, Andrew POLSON, Helga E. RAAB, Susan D. SPENCER
  • ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
    Publication number: 20220251197
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: April 20, 2022
    Publication date: August 11, 2022
    Applicant: Genentech, Inc.
    Inventors: Yvonne CHEN, Mark DENNIS, David DORNAN, Kristi ELKINS, Jagat Reddy JUNUTULA, Andrew POLSON, Bing ZHENG
  • Anti-B7-H4 Antibodies and Immunoconjugates
    Publication number: 20220251213
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: February 22, 2022
    Publication date: August 11, 2022
    Applicant: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • Anti-B7-H4 Antibodies and Immunoconjugates
    Publication number: 20220162318
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: December 10, 2021
    Publication date: May 26, 2022
    Applicant: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • Anti-B7-H4 antibodies and immunoconjugates
    Patent number: 11286302
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: March 29, 2022
    Assignee: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
    Publication number: 20220040153
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: April 14, 2021
    Publication date: February 10, 2022
    Applicant: Genentech, Inc.
    Inventors: Andrew POLSON, Shang-Fan YU, Yu-Waye CHU, Michael WENGER, Jamie Harue HIRATA, Dan LU
  • HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
    Publication number: 20220023437
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Application
    Filed: April 19, 2021
    Publication date: January 27, 2022
    Applicant: Genentech, Inc.
    Inventors: Yvonne CHEN, Mark DENNIS, Kristi ELKINS, Jagath Reddy JUNUTULA, Andrew POLSON, Bing ZHENG
  • Anti-B7-H4 antibodies and immunoconjugates
    Patent number: 11230600
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: January 25, 2022
    Assignee: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
    Publication number: 20210346352
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: May 10, 2021
    Publication date: November 11, 2021
    Applicant: Genentech, Inc.
    Inventors: Andrew POLSON, Shang-Fan YU, Yu-Waye CHU, Michael WENGER, Jamie Harue HIRATA, Dan LU
  • Anti-CLL-1 antibodies and immunoconjugates
    Patent number: 11084877
    Abstract: The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: January 17, 2019
    Date of Patent: August 10, 2021
    Assignee: Genentech, Inc.
    Inventors: Bing Zheng, Andrew Polson, Cecilia Chiu, Wei-Ching Liang, Yan Wu
  • Methods of using anti-CD79b immunoconjugates
    Patent number: 11000510
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: May 11, 2021
    Assignee: Genentech, Inc.
    Inventors: Andrew Polson, Shang-Fan Yu, Yu-Waye Chu, Michael Wenger, Jamie Harue Hirata, Dan Lu
  • Humanized anti-CD79b antibodies and immunoconjugates and methods of use
    Patent number: 10981987
    Abstract: The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: April 20, 2021
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chen, Mark Dennis, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng
  • Anti-CD79b antibodies and methods of use
    Patent number: 10941199
    Abstract: The invention provides anti-CD79b antibodies and methods of using the same.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: March 9, 2021
    Assignee: Genentech, Inc.
    Inventors: Liping L. Sun, Yvonne Man-Yee Chen, Mark S. Dennis, Allen J. Ebens, Jr., Andrew Polson
  • Anti-CD79B antibodies and immunoconjugates and methods of use
    Patent number: RE48558
    Abstract: The present invention is directed to compositions of matter comprising immunoconjugates comprising an anti-CD79b antibody comprising: (i) an HVR-L1 sequence of KASQSVDYEGDSFLN (SEQ ID NO: 194), (ii) an HVR-L2 sequence of AASNLES (SEQ ID NO: 195), (iii) an HVR-L3 sequence of QQSNEDPLT (SEQ ID NO: 196), (iv) an HVR-H1 sequence of GYTFSSYWIE (SEQ ID NO: 202), (v) an HVR-H2 sequence of GEILPGGGDTNYNEIFKG (SEQ ID NO: 203), and (vi) an HVR-H3 sequence of TRRVPIRLDY (SEQ ID NO: 204) and to methods of using those compositions of matter for the treatment of hematopoietic tumor in mammals.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: May 18, 2021
    Assignee: GENENTECH, INC.
    Inventors: Yvonne Chen, Mark Dennis, David Dornan, Kristi Elkins, Jagath Reddy Junutula, Andrew Polson, Bing Zheng